ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03233724
Brief Title: The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer

First Submitted : July 28, 2017
First Submitted that Met QC Criteria : July 28, 2017
First Posted : July 31, 2017

Last Update Submitted that Met QC Criteria : August 28, 2018
Last Update Posted : August 29, 2018